ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

Internal Friction and Mechanical Strength of Hydrogenated Ti-Rich Multicomponent Glassy Alloys (2006)

Hasegawa, Masuyuki ; Takeuchi, M. ; Nagata, D. ; [et al.]

s.l. ; Stafa-Zurich, Switzerland

Key engineering materials Vol. 319 (Sept. 2006), p. 139-144

add to mindlist on the mindlist

Details

ISSN: 1013-9826

Source: Scientific.Net: Materials Science & Technology / Trans Tech Publications Archiv 1984-2008

Topics: Mechanical Engineering, Materials Science, Production Engineering, Mining and Metallurgy, Traffic Engineering, Precision Mechanics

Notes: The hydrogen-induced internal friction and mechanical strength of the Ti-richTi34Zr11Cu47Ni8 and (Ti34Zr11Cu47Ni8)98Si2 hydrogenated glassy alloys have been investigated. It isfound that the tensile strength is more than 0.8 GPa at room temperature when the hydrogen content isbelow about 20 at% for both alloys. The frequency dependence of peak temperature of thehydrogen-induced internal friction of (Ti34Zr11Cu47Ni8)98Si2-17.3 at%H hydrogenated glassy alloyshas been clarified. Activation energy and pre-exponential factor are estimated to be 0.35 eV and1.3x10-12, respectively. Compared with these values with those of Zr40Cu49Al10Si1 hydrogenatedglassy alloys which show an internal friction peak around 300 K at about 300 Hz, it is found that theactivation energy is much smaller than that of the latter although the pre-exponential factor is almostthe same. Considering their similar composition and different component (Al), it is suggested that thecomponent Al of the latter glassy alloys is effective for the higher activation energy which results inthe increase of the peak temperature

Type of Medium: Electronic Resource

URL: http://www.tib-hannover.de/fulltexts/2011/0528/01/51/transtech_doi~10.4028%252Fwww.scientific.net%252FKEM.319.139.pdf

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease (2005)

Wada, T. ; Sasaki, M. ; Kataoka, H. ; [et al.]

Oxford, UK : Blackwell Publishing Ltd

Alimentary pharmacology & therapeutics 21 (2005), S. 0

add to mindlist on the mindlist

Details

ISSN: 1365-2036

Source: Blackwell Publishing Journal Backfiles 1879-2005

Topics: Medicine

Notes: Background : The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged.Aim : To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease.Patients and methods : A randomized, open-label trial was conducted. Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks. The Short Form-36 Health Survey and Gastrointestinal Symptom Rating Scale administered at baseline and after 8 weeks of treatment as well as a symptom questionnaire were conducted daily.Results : Short Form-36 revealed that gastro-oesophageal reflux disease has severe impact on health-related quality of life. Thirty-nine subjects (77%) were endoscopically diagnosed as non-erosive gastro-oesophageal reflux disease. The mean Gastrointestinal Symptom Rating Scale abdominal pain, and indigestion score of non-erosive gastro-oesophageal reflux disease significantly improved in famotidine-treated patients (P 〈 0.05), but not in the omeprazole. There was no significant change regarding improved heartburn symptoms of non-erosive gastro-oesophageal reflux disease between treatments in the daytime or night-time.Conclusion : Famotidine and omeprazole were both effective in improving symptoms of gastro-oesophageal reflux disease, particularly non-erosive gastro-oesophageal reflux disease.